You have 9 free searches left this month | for more free features.

Lung Cancer Squamous Cell

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non-squamous NSCLC, Epithelial Ovarian Cancer Trial (AMG 794)

Not yet recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • Epithelial Ovarian Cancer
  • AMG 794
  • Orange, California
    University of California at Irvine
Jan 25, 2023

Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

Not yet recruiting
  • Diffuse Astrocytoma, IDH-Mutant
  • +20 more
  • NEO212 Oral Capsule
  • +8 more
  • (no location specified)
Sep 18, 2023

Non-metastatic, Non-recurrent Lung and Esophageal Cancer

Recruiting
  • Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8
  • +55 more
  • Biospecimen Collection
  • +3 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
Jan 5, 2023

Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)

Active, not recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • FSRT combined with Bevacizumab
  • Guangzhou, China
    Sun Yat-sen University
Nov 25, 2022

Metastatic Squamous Non-Small Cell Lung Carcinoma Trial in Chicago (Cabozantinib 40 MG, Pembrolizumab 200mg)

Recruiting
  • Metastatic Squamous Non-Small Cell Lung Carcinoma
  • Cabozantinib 40 MG
  • Pembrolizumab 200mg
  • Chicago, Illinois
    University of Illinois at Chicago
Jan 20, 2023

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)

Recruiting
  • Advanced Non-squamous Non-Small-Cell Lung Cancer
  • Jinan, Shandong, China
    The First Affiliated Hospital of Shandong First Medical Universi
Dec 4, 2022

Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)

Not yet recruiting
  • Lung Cancer, Non-squamous, Non-small Cell
  • (no location specified)
Nov 22, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

NSCLC Trial in Guangzhou (Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Guangzhou, Guang Dong, China
    Sun Yat-sen University Cancer Center
Nov 3, 2022

NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Squamous Cell Carcinoma
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 26, 2022

NSCLC Metastatic Trial (bevacizumab plus nab-paclitaxel and platinum)

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
  • bevacizumab plus nab-paclitaxel and platinum
  • (no location specified)
Jun 2, 2022

Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, NSCLC (NSCLC) Trial in Amsterdam (BI 765063, Ezabenlimab, [89Zr]Zr-

Recruiting
  • Carcinoma, Squamous Cell of Head and Neck (HNSCC)
  • +2 more
  • BI 765063
  • +4 more
  • Amsterdam, Netherlands
    Amsterdam UMC Locatie VUMC
Jan 9, 2023

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Lung Cancer, Non Small Cell Lung Cancer, Adenocarcinoma of Lung Trial run by the National Cancer Institute (NCI) (LMB-100,

Active, not recruiting
  • Lung Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 4, 2022

Cervical Cancer, Head and Neck Squamous Cell Carcinoma, NSCLC Trial in Boston, Saint Louis (ITIL-168)

Withdrawn
  • Cervical Cancer
  • +2 more
  • ITIL-168
  • (no location specified)
Dec 16, 2022

Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer

Active, not recruiting
  • Metastatic Lung Non-Small Cell Squamous Carcinoma
  • +7 more
  • Los Angeles, California
  • +9 more
Dec 17, 2022

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma Trial (XNW5004, Pembrolizumab 25 mg/mL Solution for

Not yet recruiting
  • Carcinoma
  • +7 more
  • XNW5004
  • Pembrolizumab 25 mg/mL Solution for Injection
  • (no location specified)
Aug 31, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Non-squamous NSCLC Trial in Nanjing (paclitaxel polymeric micelles for injection)

Not yet recruiting
  • Non-squamous NSCLC
  • paclitaxel polymeric micelles for injection
  • Nanjing, Jiangsu, China
  • +1 more
Mar 13, 2023

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung

Recruiting
  • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Metastatic Non-squamous Lung Cancer Trial in Villejuif (Pembrolizumab 200 mg Q6W, Pemetrexed 500 mg/m^2 Q3W, Pembrolizumab 200

Not yet recruiting
  • Metastatic Non-squamous Lung Cancer
  • Pembrolizumab 200 mg Q6W
  • +2 more
  • Villejuif, Val-de-Marne, France
    Institut Gustave Roussy
Jan 11, 2023

Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Stage I Cutaneous Squamous Cell Carcinoma of the Head and

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +17 more
  • Best Practice
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 19, 2022